Loading
A phase 1/2 trial of COM701 in ovarian cancer, run by Compugen Ltd, now recruiting.
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer is a phase 1/2 interventional study registered as NCT06888921 by Compugen Ltd, with 60 participants planned, started 2025-07-21 and due to reach its primary completion in 2027-03. Interventions recorded: COM701 and Normal Saline.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Platinum-sensitive ovarian cancer, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/